CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, ANALYSIS

Market News

Global Clostridioides Difficile Infection Treatment Market: Key Developments

In October 2022, Acurx Pharmaceuticals, Inc., a biotechnology company, presented the poster as well as an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference highlighting new information about its lead antibiotic ibezapolstat relating to its selectivity against gram-positive gut microbiota including clostridioides difficile infection, C. coccoidies infection, and C. leptum infection groups treatment.

In November, 2022, the Combatting Bacterial Resistance in Europe Clostridioides Difficile Infection (COMBACTE-Clostridioides Difficile Infection), a European clinical research organization, celebrated November month as Clostridioides difficile awareness month.

In October, 2022, McGill University Health Centre/Research Institute of the McGill University Health Centre, in collaboration with the Canadian Institutes of Health Research (CIHR), a federal agency, initiated the clinical trial study “Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (TAPER-V)”. The Canadian Institutes of Health Research (CIHR) announced the positive phase 2 trial in October 2022, and the study is currently in the Phase 3 trial, which is estimated to get completed in March 2024.

For instance, in January 2020, Merck & Co., Inc., biopharmaceutical companies, based in the U.S. received the U.S. Food and Drug Administration (FDA) approval for the DIFICID (fidaxomicin) indicated for the treatment of the Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.